Condition: Rectal Cancer · Sponsor: Weill Medical College of Cornell University
Enrolled patients will receive upfront (week 1) short-course radiotherapy to gross pelvic disease (25Gy in 5fx) in combination with AB928 (150 mg orally, once daily as part of a continuous dose regimen). This will be followed by consolidation chemotherapy (weeks 3-20) with mFOLFOX x9 cycles in combination with AB928 and AB122.
This description comes directly from the study's public registry record.
Fabiana Gregucci, M.D. · 646- 962-3110 · fgr4002@med.cornell.edu
Dakota Trick, M.S. · 646-962-2196 · dat4015@med.cornell.edu
Always discuss trial participation with your own doctor first.
| Weill Cornell Medical College | New York, New York, United States | Recruiting |
| Brooklyn Methodist Hospital - NewYork Presbyterian | New York, New York, United States | Recruiting |
| New York Presbyterian Hospital - Queens | New York, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05024097